Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study

Korean Journal of Internal Medicine

Volumn 29, Issue 6, 2014, Pages 754-763

  Lee, Hae Young ^a   Cho, Hyun Jai ^a   Kim, Hee Yul ^b   Jeon, Hee Kyung ^c   Shin, Joon Han ^d   Kang, Suk Min ^e   Baek, Sang Hong ^f  

^a Seoul National University Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d Ajou University Medical Center   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f The Catholic University of Korea   (South Korea)

Author keywords

Exercise capacity; Heart failure; Hydroxymethylglutaryl CoA reductase inhibitors; Pitavastatin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; BIOLOGICAL MARKER; QUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR PARAMETERS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG MEGADOSE; EXERCISE; FEMALE; FUNCTIONAL STATUS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR END SYSTOLIC DIMENSION; LOW DRUG DOSE; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONVALESCENCE; DOWN REGULATION; DRUG EFFECTS; DYSLIPIDEMIAS; EXERCISE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; DOWN-REGULATION; DYSLIPIDEMIAS; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PRAVASTATIN; PROSPECTIVE STUDIES; QUINOLINES; RECOVERY OF FUNCTION; REPUBLIC OF KOREA; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84908555280     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2014.29.6.754     Document Type: Article

References (30)

1. McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail 2011;13:929-936.
2. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
3. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
5. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 2003;5:372-378.
6. Laufs U, Kilter H, Konkol C, Wassmann S, Bohm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002;53:911-920.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009.
9. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316.
10. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261.
11. Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239.
12. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415-426.
13. Bonsu KO, Kadirvelu A, Reidpath DD. Statins in heart failure: do we need another trial? Vasc Health Risk Manag 2013;9:303-319.
14. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-1573.
15. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-224.
16. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18 Suppl:S137-S144.
17. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol 2010;21:324-328.
18. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002;162:373-379.
19. Iglesias P, Diez JJ. New drugs for the treatment of hypercholesterolaemia. Expert Opin Investig Drugs 2003;12:1777-1789.
20. Kim MK, Kim B, Lee JY, et al. Tissue Doppler-derived E/ e’ ratio as a parameter for assessing diastolic heart failure and as a predictor of mortality in patients with chronic kidney disease. Korean J Intern Med 2013;28:35-44.
21. Yang JH, Choi JH, Ki YW, et al. Plasma N-terminal pro-B-type natriuretic peptide is predictive of perioperative cardiac events in patients undergoing vascular surgery. Korean J Intern Med 2012;27:301-310.
22. Takano H, Mizuma H, Kuwabara Y, et al. Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013;77:917-925.
23. Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009;104:1708-1716.
24. Ashton E, Windebank E, Skiba M, et al. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol 2011;146:404-407.
25. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172:1180-1182.
26. Perez AC, Jhund P, Preiss D, Kjekshus J, McMurray JJ. Effect of rosuvastatin on fatigue in patients with heart failure. J Am Coll Cardiol 2013;61:1121-1122.
27. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-2797.
28. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-125.
29. Kihara Y. Statin therapy in chronic heart failure: frog prince or bare frog? Circ J 2013;77:895-897.
30. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-1940.